Complex Regional Pain Syndrome - Pipeline Review, H2 2018

  • ID: 4590305
  • Report
  • 37 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abiogen Pharma SpA
  • Grunenthal GmbH
  • Piramal Enterprises Ltd
  • Tetra Bio-Pharma Inc
  • MORE
Complex Regional Pain Syndrome - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Complex Regional Pain Syndrome - Pipeline Review, H2 2018, provides an overview of the Complex Regional Pain Syndrome (Central Nervous System) pipeline landscape.

Complex regional pain syndrome (CRPS) is a chronic pain condition that most often affects one limb usually after an injury. CRPS is divided into two types: CRPS-I (Individuals without a confirmed nerve injury) and CRPS-II (when there is an associated, confirmed nerve injury). Symptoms include stiffness in affected joints, changes in nail and hair growth patterns, dystonia and abnormal sweating pattern. Treatment includes bisphosphonates, non-steroidal anti-inflammatory drugs, opioids and local anesthetic creams.

Report Highlights:

This latest pipeline guide Complex Regional Pain Syndrome - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Complex Regional Pain Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Complex Regional Pain Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Complex Regional Pain Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Complex Regional Pain Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Complex Regional Pain Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Complex Regional Pain Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Complex Regional Pain Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Complex Regional Pain Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Complex Regional Pain Syndrome (Central Nervous System)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Complex Regional Pain Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Complex Regional Pain Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abiogen Pharma SpA
  • Grunenthal GmbH
  • Piramal Enterprises Ltd
  • Tetra Bio-Pharma Inc
  • MORE
Introduction

Report Coverage

Complex Regional Pain Syndrome - Overview

Complex Regional Pain Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Complex Regional Pain Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Complex Regional Pain Syndrome - Companies Involved in Therapeutics Development

Abiogen Pharma SpA

Grunenthal GmbH

Piramal Enterprises Ltd

Tetra Bio-Pharma Inc

Complex Regional Pain Syndrome - Drug Profiles

hydromorphone hydrochloride (intrathecal infusion) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

neridronic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NTRX-07 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T-121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Complex Regional Pain Syndrome - Dormant Projects

Complex Regional Pain Syndrome - Product Development Milestones

Featured News & Press Releases

Jun 12, 2018 : Grunenthal Initiates Pivotal Phase III Trials in Complex Regional Pain Syndrome

Mar 14, 2018 : Tetra Bio-Pharma Announces FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome

Dec 16, 2016: Grünenthal Receives Breakthrough Therapy Designation From U.S. FDA for Neridronic Acid for the Treatment of CRPS

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Complex Regional Pain Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Complex Regional Pain Syndrome - Pipeline by Abiogen Pharma SpA, H2 2018

Complex Regional Pain Syndrome - Pipeline by Grunenthal GmbH, H2 2018

Complex Regional Pain Syndrome - Pipeline by Piramal Enterprises Ltd, H2 2018

Complex Regional Pain Syndrome - Pipeline by Tetra Bio-Pharma Inc, H2 2018

Complex Regional Pain Syndrome - Dormant Projects, H2 2018

List of Figures

Number of Products under Development for Complex Regional Pain Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abiogen Pharma SpA
  • Grunenthal GmbH
  • Piramal Enterprises Ltd
  • Tetra Bio-Pharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll